BioSpace News Archive

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive data from the company’s late-stage bladder cancer trial (QUILT-3.032).

LYNPARZA® (olaparib) plus Abiraterone Reduced Risk of Disease Progression by 34% vs. Standard-of-Care in 1st-Line Metastatic Castration-Resistant Prostate Cancer.

Adcentrx Therapeutics (“Adcentrx”), and AvantGen, announced today a three-year, multi-target partnership for the discovery of antibodies to be developed into novel ADC therapeutic candidates.

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company developing niche generic products, announced results for the third quarter of fiscal year 2022 ended December 31, 2021.

Biotricity, Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced financial results for its 2022 fiscal year’s third quarter ended December 31, 2021.

Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced the publication of the PICTURE study in Orphanet Journal of Rare Disease.

The Heart Institute at Children’s Hospital Colorado has performed its 500th pediatric heart transplant, a milestone that only a few centers across the country have reached.

Vivacitas Oncology, Inc., a privately-held biopharmaceutical company focused on tough-to-treat cancers, will present at the upcoming 2022 BIO CEO & Investor Conference, which will be held in New York City on February 14-17, 2022.

ScreenPoint Medical’s Transpara AI decision support system can help radiologists to identify potential breast cancers earlier and faster, according to a new study published in Radiology.

Actym Therapeutics, a privately-held biotechnology company focused on the discovery and development of novel immuno-oncology therapies to treat cancer, announced today that the United States Patent and Trademark Office (USPTO) has granted a patent that protects the company’s therapeutic technology platform.